Selected research
Industry Research
Multiple Sclerosis Therapeutics Industry Research Report 2026
Market perspective
The global Multiple Sclerosis Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Multiple Sclerosis Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Multiple Sclerosis Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Multiple Sclerosis Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Multiple Sclerosis Therapeutics include Biogen Idec, Sanofi Genzyme, Teva Pharmaceuticals, AbbVie, Bayer, Pfizer, Merck and Novartis, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Multiple Sclerosis Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Multiple Sclerosis Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Multiple Sclerosis Therapeutics Market by Company
Biogen Idec
Sanofi Genzyme
Teva Pharmaceuticals
AbbVie
Bayer
Pfizer
Merck
Novartis
Multiple Sclerosis Therapeutics Segment by Type
Beta Interferon
Monoclonal Antibodies
Antineoplastic Agents
Corticosteroids
Others
Multiple Sclerosis Therapeutics Segment by Application
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Multiple Sclerosis Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Multiple Sclerosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Beta Interferon
- Monoclonal Antibodies
- Antineoplastic Agents
- Corticosteroids
- Others
Applications
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
Companies covered
- Biogen Idec
- Sanofi Genzyme
- Teva Pharmaceuticals
- AbbVie
- Bayer
- Pfizer
- Merck
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Multiple Sclerosis Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Beta Interferon
- 2.2.3 Monoclonal Antibodies
- 2.2.4 Antineoplastic Agents
- 2.2.5 Corticosteroids
- 2.2.6 Others
- 2.3 Multiple Sclerosis Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacies
- 2.3.3 Retail Pharmacies
- 2.3.4 e-Commerce
- 2.4 Assumptions and Limitations
3 Multiple Sclerosis Therapeutics Breakdown Data by Type
- 3.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2027-2032)
4 Multiple Sclerosis Therapeutics Breakdown Data by Application
- 4.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Multiple Sclerosis Therapeutics Market Perspective (2021-2032)
- 5.2 Global Multiple Sclerosis Therapeutics Growth Trends by Region
- 5.2.1 Global Multiple Sclerosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Multiple Sclerosis Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Multiple Sclerosis Therapeutics Market Dynamics
- 5.3.1 Multiple Sclerosis Therapeutics Industry Trends
- 5.3.2 Multiple Sclerosis Therapeutics Market Drivers
- 5.3.3 Multiple Sclerosis Therapeutics Market Challenges
- 5.3.4 Multiple Sclerosis Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue
- 6.1.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Multiple Sclerosis Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Multiple Sclerosis Therapeutics Head Office and Area Served
- 6.4 Global Multiple Sclerosis Therapeutics Players, Product Type & Application
- 6.5 Global Multiple Sclerosis Therapeutics Manufacturers Established Date
- 6.6 Global Multiple Sclerosis Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Multiple Sclerosis Therapeutics Market Size (2021-2032)
- 7.2 North America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Multiple Sclerosis Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Multiple Sclerosis Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Multiple Sclerosis Therapeutics Market Size (2021-2032)
- 8.2 Europe Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Multiple Sclerosis Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Multiple Sclerosis Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Multiple Sclerosis Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Multiple Sclerosis Therapeutics Market Size (2021-2032)
- 10.2 South America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Multiple Sclerosis Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Multiple Sclerosis Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Multiple Sclerosis Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Biogen Idec
- 12.1.1 Biogen Idec Company Information
- 12.1.2 Biogen Idec Business Overview
- 12.1.3 Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.1.4 Biogen Idec Multiple Sclerosis Therapeutics Product Portfolio
- 12.1.5 Biogen Idec Recent Developments
- 12.2 Sanofi Genzyme
- 12.2.1 Sanofi Genzyme Company Information
- 12.2.2 Sanofi Genzyme Business Overview
- 12.2.3 Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.2.4 Sanofi Genzyme Multiple Sclerosis Therapeutics Product Portfolio
- 12.2.5 Sanofi Genzyme Recent Developments
- 12.3 Teva Pharmaceuticals
- 12.3.1 Teva Pharmaceuticals Company Information
- 12.3.2 Teva Pharmaceuticals Business Overview
- 12.3.3 Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.3.4 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product Portfolio
- 12.3.5 Teva Pharmaceuticals Recent Developments
- 12.4 AbbVie
- 12.4.1 AbbVie Company Information
- 12.4.2 AbbVie Business Overview
- 12.4.3 AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.4.4 AbbVie Multiple Sclerosis Therapeutics Product Portfolio
- 12.4.5 AbbVie Recent Developments
- 12.5 Bayer
- 12.5.1 Bayer Company Information
- 12.5.2 Bayer Business Overview
- 12.5.3 Bayer Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.5.4 Bayer Multiple Sclerosis Therapeutics Product Portfolio
- 12.5.5 Bayer Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.6.4 Pfizer Multiple Sclerosis Therapeutics Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Merck
- 12.7.1 Merck Company Information
- 12.7.2 Merck Business Overview
- 12.7.3 Merck Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.7.4 Merck Multiple Sclerosis Therapeutics Product Portfolio
- 12.7.5 Merck Recent Developments
- 12.8 Novartis
- 12.8.1 Novartis Company Information
- 12.8.2 Novartis Business Overview
- 12.8.3 Novartis Revenue in Multiple Sclerosis Therapeutics Business (2021-2026)
- 12.8.4 Novartis Multiple Sclerosis Therapeutics Product Portfolio
- 12.8.5 Novartis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst